BioSpace News Archive

Biotech Bay

Avail Medsystems to Participate at Upcoming Industry and Investor Conferences

Avail, the digital hub of the operating room enabling the medical technology (MedTech) and healthcare industries to work smarter to advance patient care, today announced that Avail’s senior management team will present at the following upcoming conferences.

October 12, 2022
·
2 min read
Pharm Country

Elysium Health™ Announces Positive Results on Its Product Basis™ Published in Hepatology

Elysium Health, Inc.™, a leading life sciences company focused on aging research, today announced that the detailed results from its clinical trial on Basis™ (NRPT) in people with non-alcoholic fatty liver disease (NAFLD) were published in Hepatology.

October 12, 2022
·
4 min read
BioCapital

Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022

Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS ® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022.

October 12, 2022
·
11 min read
Business

Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2

Glaukos Corporation plans to release third quarter 2022 financial results after the market close on Wednesday, November 2, 2022.

October 12, 2022
·
1 min read
Lone Star Bio

Orthofix and MTF Biologics Recognized with 2022 Spine Technology Award for Virtuos Lyograft – a First-of-Its-Kind, Shelf-Stable and Complete Autograft Substitute for Spine and Orthopedic Procedures

Orthofix Medical Inc. today announced that the Virtuos ™ Lyograft has received the 2022 Spine Technology Award from Orthopedics This Week, the most widely read publication in the Orthopedics industry.

October 12, 2022
·
6 min read
Linear Health Sciences Recognized for Leading the Way to Safer IV Treatment for Children

Device Intended to Reduce Risk of IV Catheter Failure and Replacement in Hospitals Recognized by Pediatrics Consortium, FDA.

October 12, 2022
·
3 min read
Antibe Provides Development Update for Otenaproxesul

Antibe Therapeutics Inc. is pleased to announce a major advance in otenaproxesul’s formulation that promises to increase its therapeutic benefit and commercial potential. Accordingly, the Company has filed a patent application that strengthens the drug’s IP protection to 2042.

October 12, 2022
·
4 min read
Drug Development

BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial

BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA ® (zanubrutinib) Compared to IMBRUVICA ® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial.

October 12, 2022
·
6 min read
Business

Repligen to Report Third Quarter 2022 Financial ResultsWebcast and Conference Call to Be Held Tuesday, November 1, 2022 at 8:30 a.m. EDT

Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2022 financial results on Tuesday, November 1, 2022.

October 12, 2022
·
2 min read
Business

Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs

Tavros Therapeutics, Inc. and Vividion Therapeutics, Inc. today announced the companies have entered into a collaboration agreement to discover or target four oncology targets across an initial five-year term.

October 12, 2022
·
5 min read